<SEC-DOCUMENT>0001144204-17-047848.txt : 20170913
<SEC-HEADER>0001144204-17-047848.hdr.sgml : 20170913
<ACCEPTANCE-DATETIME>20170913161948
ACCESSION NUMBER:		0001144204-17-047848
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20170913
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170913
DATE AS OF CHANGE:		20170913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FENNEC PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001211583
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32295
		FILM NUMBER:		171083359

	BUSINESS ADDRESS:	
		STREET 1:		PO BOX 13628
		STREET 2:		68 TW ALEXANDER DRIVE
		CITY:			RESEARCH TRIANGLE PARK
		STATE:			NC
		ZIP:			27709
		BUSINESS PHONE:		(919) 636-4530

	MAIL ADDRESS:	
		STREET 1:		PO BOX 13628
		STREET 2:		68 TW ALEXANDER DRIVE
		CITY:			RESEARCH TRIANGLE PARK
		STATE:			NC
		ZIP:			27709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FENNEC PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20140903

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADHEREX TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20021223
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v475143_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B><BR>
<FONT STYLE="font-size: 16pt"><B>Form 8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Current Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): September 13, 2017</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>FENNEC
PHARMACEUTICALS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><B>001-32295</B><BR>
(Commission File Number)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; width: 33%"><FONT STYLE="font-size: 10pt"><B>British Columbia, Canada </B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 34%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 33%"><FONT STYLE="font-size: 10pt"><B>20-0442384</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of</FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>PO Box 13628, 68 TW Alexander Drive,</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Research Triangle Park, NC</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 34%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>27709</B></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code:</B> (<B>919) 636-4530</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD><FONT STYLE="font-family: Wingdings"></FONT>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD COLSPAN="5">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 1%; text-align: right"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT> </FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font-size: 10pt"><B>Item 8.01</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Other Events.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 11, 2017,
Fennec Pharmaceuticals Inc. (&ldquo;Fennec&rdquo;) issued a press release announcing that its shares of common stock were approved
for listing on the Nasdaq Capital Market (&quot;Nasdaq&quot;). Fennec commenced trading on Nasdaq under the symbol &ldquo;FENC&rdquo;
on September 13, 2017. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 13, 2017,
Fennec announced the preliminary results of the SIOPEL 6 study on PEDMARK<SUP>TM</SUP> (sodium thiosulfate) to be presented at
the 49th congress of the international society of pediatric oncology (SIOP) 2017 meeting. The SIOP conference committee has advised
of the acceptance of a SIOPEL 6 abstract for presentation during the late breaker session on Saturday, October 14, 2017 at SIOP
2017 in Washington, DC. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements
and Exhibits.</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.75in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exhibits.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Description</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 96px"><A HREF="v475143_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Exhibit 99.1</FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="v475143_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release dated September 11, 2017</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="v475143_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Exhibit 99.2</FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="v475143_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release dated September 13, 2017</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 39.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FENNEC
    PHARMACEUTICALS INC.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    September 13, 2017</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 30%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Rostislav Raykov </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rostislav
    Raykov</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v475143_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 49.5pt; width: 90.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FENNEC PHARMACEUTICALS ANNOUNCES LISTING
ON THE NASDAQ CAPITAL MARKET </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Symbol; color: #4C4C4C">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #4C4C4C">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Trading on Nasdaq under the symbol &quot;FENC&quot; is expected
to commence on September 13, 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research Triangle Park, NC, September
11, 2017 &ndash; </I></B>Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the
development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced
that its shares of common stock were approved for listing on the Nasdaq Capital Market (&quot;Nasdaq&quot;). Trading on the Nasdaq
under the symbol &quot;FENC&quot; is expected to commence on September 13, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;We
look forward to the expanded visibility, improved liquidity, and the potential diversification of our stockholder base that the
trading on the Nasdaq may provide as we continue to focus on increasing stockholder value,&quot; stated Rosty Raykov, CEO of Fennec.
&ldquo;Our listing on the Nasdaq represents a significant corporate milestone as we continue our commitment towards serving an
unmet medical need for pediatric patients with cisplatin chemotherapy pending the SIOPEL 6 results in Q4 2017.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Fennec's
common stock, which has been trading on the OTCB Marketplace (the &quot;OTCQB&quot;) since January 2009, will continue to trade
on the OTCQB until the market closes on September 12, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Fennec Pharmaceuticals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fennec
Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention
of platinum-induced ototoxicity in pediatric patients. STS has received Orphan Drug Designation in the US in this setting. For
more information, please visit </FONT><U>www.fennecpharma.com</U><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Sodium Thiosulfate (STS)</B><BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cisplatin and other platinum compounds
are essential chemotherapeutic components for many pediatric malignancies. &nbsp;Unfortunately, platinum-based therapies cause
ototoxicity in many patients, and are particularly harmful to the survivors of pediatric cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S. and Europe there is estimated
that over 7,000 children are diagnosed with local cancers that may receive platinum based chemotherapy. &nbsp;&nbsp;Localized cancers
that receive platinum agents may have overall survival rates of greater than 80% further emphasizing the quality of life after
treatment. The incidence of hearing loss in these children depends upon the dose and duration of chemotherapy, and many of these
children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive,
technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young
children at critical stages of development lack speech language development and literacy, and older children and adolescents lack
social-emotional development and educational achievement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">STS has been studied by cooperative groups
in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL
6. Both studies are closed to recruitment. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with
intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor,
osteosarcoma, neuroblastoma, and medulloblastoma. &nbsp;SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Forward looking statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except for historical information described
in this press release, all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties
inherent in the Company&rsquo;s business that could cause actual results to vary, including such risks that regulatory and guideline
developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company&rsquo;s patents
and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company&rsquo;s
products will not be as large as expected, the Company&rsquo;s products will not be able to penetrate one or more targeted markets,
revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital requirements
in different countries and municipalities, the proposed sale to Elion may not be completed and other risks detailed from time to
time in the Company&rsquo;s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the
year ended December 31, 2016. Fennec Pharmaceuticals, Inc. disclaims any obligation to update these forward-looking statements
except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a more detailed discussion of related
risk factors, please refer to our public filings available at <U>www.sec.gov</U> and <U>www.sedar.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rosty Raykov</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fennec Pharmaceuticals Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">T: (919) 636-5144</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>v475143_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FENNEC ANNOUNCES PRELIMINARY RESULTS
OF SIOPEL 6 STUDY ON PEDMARK<SUP>TM</SUP> (sodium thiosulfate) TO BE PRESENTED AT THE 49<SUP>TH</SUP> CONGRESS OF THE INTERNATIONAL
SOCIETY OF PEDIATRIC ONCOLOGY (SIOP) 2017 MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>SIOPEL 6 shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing
loss without any evidence of tumor protection</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>Among the first 94 evaluable patients, hearing loss occurred in 29/44=65.9% under Cisplatin Arm and in 19/50=38.0% under
Cis+STS Arm, corresponding to a relative risk of 0.57 (P=0.0069)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>Late Breaker Oral Presentation on Saturday, October 14, 2017 during SIOP 2017 in Washington, DC</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Research Triangle Park, NC, September
13, 2017&ndash; </I></B>Fennec Pharmaceuticals Inc. (TSX: FRX, NASDAQ: FENC), a specialty pharmaceutical company focused on the
development of PEDMARK<SUP>TM</SUP> (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity
in pediatric patients, announced today that the SIOP conference committee has advised of the acceptance of a SIOPEL 6 abstract
for presentation during the late breaker session on Saturday, October 14, 2017 at SIOP 2017 in Washington, DC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In particular, Penelope Brock, M.D.,&nbsp;PhD,
International Chair of SIOPEL, will present &ldquo;<B>SODIUM THIOSULFATE (STS) AS OTOPROTECTANT TO REDUCE THE INCIDENCE OF CISPLATIN-INDUCED
HEARING LOSS: FINAL RESULTS OF THE SIOPEL 6 TRIAL FOR STANDARD RISK HEPATOBLASTOMA (SR-HB</B>).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Details of Abstract 20 of the late
breaker session posted on the SIOP 2017 website today are as follows:<BR>
Place: Marriott Wardman Park Hotel, Marriott Salon 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Date and Time: October 14, 2017, 17:30-17:45</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Background / Objectives:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Background: Bilateral high-frequency hearing loss is a serious
permanent side-effect of cisplatin therapy; particularly debilitating when occurring in young children. STS has been shown to reduce
cisplatin induced hearing loss. SIOPEL 6 is a phase III randomised trial to assess the efficacy of STS in reducing ototoxicity
in young children treated with cisplatin (Cis) for SR-HB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Design / Methods:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Methods: Newly diagnosed patients with SR-HB, defined as tumour
limited to PRETEXT I, II or III, no portal or hepatic vein involvement, no intra-abdominal extrahepatic disease, AFP &gt;100ng/ml
and no metastases, were randomised to Cis or Cis+STS for 4 preoperative and 2 postoperative courses. Cisplatin 80mg/m2 was administered
over 6 hours, STS 20g/m2 was administered intravenously over 15 minutes exactly 6 hours after stopping cisplatin. Tumour response
was assessed after 2 and 4 preoperative cycles with serum AFP and liver imaging. In case of progressive disease (PD), STS was to
be stopped and doxorubicin 60mg/m2 combined to cisplatin. The primary endpoint is centrally reviewed absolute hearing threshold,
at the age of &ge;3.5 years by pure tone audiometry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;<IMG SRC="image_004.jpg" ALT=""></TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Results: One hundred and nine randomised patients (52 Cis and
57 Cis+STS) are evaluable. The combination of Cis+STS was generally well tolerated. With a follow up of 52months, 3yr EFS is Cis
80.4% (95%CI 66.6%-88.9%) and Cis+STS 81.9% (68.8%-89.9%); 3yr OS is Cis 92.3% (80.8%-97.0%) and Cis+STS 98.2% (87.8%-99.7%). Treatment
failure defined as PD at 4 cycles was equivalent in both arms. Among the first 94 evaluable patients, hearing loss occurred in
29/44=65.9% under Cis and in 19/50=38.0% under Cis+STS, corresponding to a relative risk of 0.57(P=0.0069). Results will be updated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conclusions:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Conclusion: This randomised phase III trial in SR-HB of cisplatin
versus cisplatin plus sodium thiosulfate shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced
hearing loss without any evidence of tumour protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PEDMARK<SUP>TM</SUP> (sodium thiosulfate/STS)</B><BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cisplatin and other platinum compounds are essential chemotherapeutic
components for many pediatric malignancies. &nbsp;Unfortunately, platinum-based therapies cause ototoxicity in many patients, and
are particularly harmful to the survivors of pediatric cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the U.S. and Europe there is estimated that over 7,000 children
are diagnosed with local cancers that may receive platinum based chemotherapy. Localized cancers that receive platinum agents may
have overall survival rates of greater than 80% further emphasizing the quality of life after treatment. The incidence of hearing
loss in these children depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing
aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal
cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children at critical stages of development
lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational
achievement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STS has been studied by cooperative groups in two Phase 3 clinical
studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies are
closed to recruitment. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with intensive cisplatin
therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma,
and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;<IMG SRC="image_004.jpg" ALT=""></TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Fennec Pharmaceuticals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fennec Pharmaceuticals, Inc., is a specialty pharmaceutical
company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric
patients. STS has received Orphan Drug Designation in the US in this setting. For more information, please visit <U>www.fennecpharma.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Forward looking statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except for historical information described in this press release,
all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties inherent in
the Company&rsquo;s business that could cause actual results to vary, including such risks that regulatory and guideline developments
may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or
approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company&rsquo;s patents
and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company&rsquo;s
products will not be as large as expected, the Company&rsquo;s products will not be able to penetrate one or more targeted markets,
revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital requirements
in different countries and municipalities, and other risks detailed from time to time in the Company&rsquo;s filings with the Securities
and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2016. Fennec Pharmaceuticals,
Inc. disclaims any obligation to update these forward-looking statements except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The scientific information discussed in this news release related
to PEDMARK<SUP>TM</SUP> is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration,
Health Canada or other regulatory body and no conclusions can or should be drawn regarding the safety or effectiveness of such
product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For a more detailed discussion of related risk factors, please
refer to our public filings available at <U>www.sec.gov</U> and <U>www.sedar.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rosty Raykov</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fennec Pharmaceuticals Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: (919) 636-5144</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (C ^@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***1W6-&=V"JHR23@ 4 1W%Q%:6[SSN$C099C7F6N:S+K-X7.5@
M3B*/T'J?<U:\2:^VK7'DP$BSC/RC^^?[Q_I6#7S&98_VS]G3?NK\?^ ?2Y=@
M?8KVE3XG^'_!"BBBO*/5'11M-*D:#+.P4#W->OVT"VUK% GW8T"#Z 8KSCPK
M:?:O$$&1E8LRG\.GZXKTROH<EI6A*IWT^X^?SFK><:?;7[PHHHKVSQ0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% ",P52S$  9)/:O./$VO'5;GR8&(M(C\O^V?
M[W^%:?B[7]Y;3+5_E'$[CO\ [/\ C^5<=7SN:8[G?L:;TZ_Y'T&68+E7MJBU
MZ?YA1117BGM!1110 4444 %%%% !1110 5ZKH5I]BT2TA(PVP,WU/)_G7FVE
M6OV[5;:VQD/( WTZG],UZU7NY+2UE4^7ZGAYS5TC3^?Z!1117OG@A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/>*->&F6_V:W;_ $N4
M=1_RS7U^OI6AK.K1:18-.^&D/$:?WF_PKR^YN);NXDGG<O(YRQ->3F>.]C'V
M4'[S_!?YGJY;@O:R]I->ZOQ9$22<GDT445\R?2A1110 4444 %%%% !1110
M4444 =1X(M/-U2:Y(XACP/\ >;_ZP-=]7.^#+3R-$\XCYIW+?@.!_(_G715]
M=EM+V>&CYZ_>?)YC5]IB9>6GW!1117<<(4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !4-U<Q6=M)<3N%CC&6-3$@#)X%>=>*->.IW/V:W;_ $2(
M\$?QMZ_3TKDQF+CAJ?,]WLCKP>%EB*G*MNIG:QJLNKW[7$F0@XC3^ZO^-9]%
M%?(3G*<G*3NV?6PA&$5&*T04445)04444 %%%% !1110 4444 %*JEV"J,L3
M@"DK6\-6GVO7[52,JC>8W_ >?YXJZ4'4FH+JR*LU3@YOHCTFRMA9V,%LO2*,
M+]<"IZ**^XBE%)(^);;=V%%%%,04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<OXOUO[);_8+=\3RC]X1_"OI]3_*MK5M2BTK
M3Y+F3DCA%_O-V%>67-Q+=W,EQ,Q:21MS&O)S3&>RA[*'Q/\ !?\ !/5RS">U
MG[6>R_%_\ BHHHKYD^E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#O?
M]IY>FSW1',TFT?1?_KDUU-4M(M/L.D6MOC#)&-P_VCR?U)J[7VF$I>RH1AY'
MQN*J^UK2GYA11170<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<U==,U*VA228$PR0 @9 S@@D]@><]J@^,/\ QX:7_P!=9/Y"N)\ ?\CSI?\
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MA7$^ /\ D>=+_P!]O_0&KMOC#_QX:7_UUD_D*XGP!_R/.E_[[?\ H#5U8?\
MW1^C.'%_\C!>L?T/H&O#/B?_ ,CM/_UQC_E7N=>&?$__ )':?_KC'_*N3+OX
MWR._-_\ =_FOU-CX/?\ (2U3_KBG\S7K=?.WAOQ3?>%YYY;&*WD:=0K>>K$
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M]E/:QK"X1A.[ DD9XPIK;_X5'K__ #]Z;_W\D_\ B*W_ (/_ /((U+_KNO\
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M<DM$9RJPC)1DTFSI****@T"LWQ%_R+.J_P#7G-_Z :TJS?$7_(LZK_UYS?\
MH!JH?$O5$5/@EZ/\F>.>$-?\2:18W$6B:1]MA>3<[_9I)-K8Z94C'%='_P )
MMX^_Z%C_ ,D)_P#XJKOP@_Y >H?]?(_]!%>BUWXFM"-62<$_O/+P>&J2H1DJ
MK7EH>7#Q?\09QM3PX(SZ_8I5_P#0FJ.3PWXZ\5L$UJ\%G9DY,988Q_N)U/\
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M1+<A6NY</<2#NWH/8=/S/>N@HHKGG-SDY2W9UTZ<:<5".R/*/&/_ "5K0_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH IZGI\6J:?):R\;AE6_NMV->5
M7-O+:7,EO,NV2-MK"O8:Y/QEHWGP?VC O[R(8E [KZ_A_+Z5Y&:X3VD/:QW7
MY?\  /6RO%^SG[*6S_/_ ()B^#K3[1KJRD?+ A?\>@_G^E>C5RO@:T\O3I[H
MCF:3:/HO_P!<G\JZJMLKI>SPR??4QS.KSXAKMH8GBR[^R^'Y@#AIB(A^/7]
M:\TKK_'5WNN+6T!^XID8?7@?R/YUR%>-FM7GQ+7;0]G*Z7)AT^^H4445YIZ(
M4444 %%%% !3D1Y'"1JSNQP%49)K=TCPI>:CMEG!MK<\[F'S-]!_4UW.G:/9
M:7'MMH0&Q@R-RQ_&O1PN65:WO2]U?UT/.Q.94J/NQ]Y_UU./TOP7=7&V2_?[
M/'_<'+G^@KL+#2+'3%Q:VZJW=SRQ_&KU%?08? T:'PK7N]SP<1C:U?XGIV6P
M4445UG(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!\)Q686YOPLMQU6/JJ?XFNHHHKZBA0IT(\E-6/F:U>I6ES384445L8A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 $@#). *\BU&Z-[J-Q<]I)"P^F>/TKTKQ!=_8]"NY0<,4V+]6X_K7EE?/
MYU5UC3^?Z'O9-2TE4^05IZ-HESK-QMC&R%3^\E(X7_$^U3:#X?FUB;>V8[5#
M\\GK[#W_ )5Z/:VL%E;I!;QB.-!@ 5SX#+G7_>5-(_G_ , Z,=F"H^Y3UE^7
M_!(M.TVVTNU$%LFT?Q,>K'U)JW117TT8J*48JR1\W*3DW*3NPHHHJB0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .0\=7>VWM;0'[[&1A].!_,_E6)X>\/2:O-YLN4M$/S-W8^@_P :
MVKO2I/$/B>9W)6RML1%O[Q')4?B376PPQV\*0Q($C0851T KQE@_K6)E6J?"
MG9>=OT_,]AXOZMAHT:?Q/5^5_P!1(((K:%(845(T&%5>@J2BBO8225D>0VV[
ML****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!L<:1+M10JY)P/4\FG444; %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" 'D# 2(  A$! Q$!_\0
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M5-T&*@L$P#CD9//\J**3&B6BBBF(**** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" 'D# 2(  A$! Q$!_\0
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M5-T&*@L$P#CD9//\J**3&B6BBBF(**** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
